[go: up one dir, main page]

WO2009055669A3 - Anticorps monoclonaux contre la protéine c activée - Google Patents

Anticorps monoclonaux contre la protéine c activée Download PDF

Info

Publication number
WO2009055669A3
WO2009055669A3 PCT/US2008/081110 US2008081110W WO2009055669A3 WO 2009055669 A3 WO2009055669 A3 WO 2009055669A3 US 2008081110 W US2008081110 W US 2008081110W WO 2009055669 A3 WO2009055669 A3 WO 2009055669A3
Authority
WO
WIPO (PCT)
Prior art keywords
monoclonal antibodies
protein
antibodies against
antibodies
unactivated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2008/081110
Other languages
English (en)
Other versions
WO2009055669A2 (fr
Inventor
Jun Xu
Charles Esmon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oklahoma Medical Research Foundation
Original Assignee
Oklahoma Medical Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA2703738A priority Critical patent/CA2703738C/fr
Priority to AU2008316661A priority patent/AU2008316661B2/en
Priority to KR1020157020430A priority patent/KR20150092358A/ko
Priority to EP08841295.2A priority patent/EP2205638B1/fr
Priority to MX2010004615A priority patent/MX2010004615A/es
Priority to JP2010531275A priority patent/JP2011500843A/ja
Priority to CN2008801210245A priority patent/CN101918453A/zh
Priority to KR1020107011548A priority patent/KR101856210B1/ko
Priority to BRPI0818865 priority patent/BRPI0818865A2/pt
Priority to RU2010121148/10A priority patent/RU2539729C2/ru
Application filed by Oklahoma Medical Research Foundation filed Critical Oklahoma Medical Research Foundation
Publication of WO2009055669A2 publication Critical patent/WO2009055669A2/fr
Publication of WO2009055669A3 publication Critical patent/WO2009055669A3/fr
Priority to IL205284A priority patent/IL205284A/en
Anticipated expiration legal-status Critical
Priority to IL220622A priority patent/IL220622A0/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)

Abstract

La présente invention concerne des anticorps monoclonaux qui se lient sélectivement et inhibent la protéine C activée sans se lier à la protéine C inactivée ou l'inhiber. D'autres anticorps inhibent à la fois la protéine C activée et l'activation de la protéine C inactivée. Les procédés de traitement utilisant ces anticorps sont décrits ici, ainsi que des procédés de criblage et de détection de ces anticorps.
PCT/US2008/081110 2007-10-26 2008-10-24 Anticorps monoclonaux contre la protéine c activée Ceased WO2009055669A2 (fr)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BRPI0818865 BRPI0818865A2 (pt) 2007-10-26 2008-10-24 Anticorpos monoclonais contra proteína c ativada.
KR1020157020430A KR20150092358A (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
EP08841295.2A EP2205638B1 (fr) 2007-10-26 2008-10-24 Anticorps monoclonaux contre la protéine c activée et non-activée
MX2010004615A MX2010004615A (es) 2007-10-26 2008-10-24 Anticuerpos monoclonales contra proteina c. activada e inactivada.
JP2010531275A JP2011500843A (ja) 2007-10-26 2008-10-24 活性化プロテインｃおよび不活性化プロテインｃに対するモノクロナール抗体
CN2008801210245A CN101918453A (zh) 2007-10-26 2008-10-24 针对活化蛋白c的单克隆抗体
KR1020107011548A KR101856210B1 (ko) 2007-10-26 2008-10-24 활성 및 비활성 단백질 ｃ에 대한 모노클로날 항체
CA2703738A CA2703738C (fr) 2007-10-26 2008-10-24 Anticorps monoclonaux contre la proteine c activee ou non activee
AU2008316661A AU2008316661B2 (en) 2007-10-26 2008-10-24 Monoclonal antibodies against activated and unactivated protein C
RU2010121148/10A RU2539729C2 (ru) 2007-10-26 2008-10-24 Моноклональные антитела против активированного протеина с
IL205284A IL205284A (en) 2007-10-26 2010-04-22 Monoclonal antibodies against activated protein c, a pharmaceutical composition comprising the same and use thereof
IL220622A IL220622A0 (en) 2007-10-26 2012-06-24 Monoclonal antibodies against activated and unactivated protein c

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98309207P 2007-10-26 2007-10-26
US60/983,092 2007-10-26

Publications (2)

Publication Number Publication Date
WO2009055669A2 WO2009055669A2 (fr) 2009-04-30
WO2009055669A3 true WO2009055669A3 (fr) 2009-09-03

Family

ID=40289112

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/081110 Ceased WO2009055669A2 (fr) 2007-10-26 2008-10-24 Anticorps monoclonaux contre la protéine c activée

Country Status (13)

Country Link
US (3) US8153766B2 (fr)
EP (1) EP2205638B1 (fr)
JP (3) JP2011500843A (fr)
KR (2) KR101856210B1 (fr)
CN (3) CN105153308A (fr)
AU (1) AU2008316661B2 (fr)
BR (1) BRPI0818865A2 (fr)
CA (1) CA2703738C (fr)
IL (2) IL205284A (fr)
MX (1) MX2010004615A (fr)
RU (2) RU2539729C2 (fr)
WO (1) WO2009055669A2 (fr)
ZA (1) ZA201105704B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3539374A1 (fr) * 2012-03-16 2019-09-18 Regeneron Pharmaceuticals, Inc. Animaux non humains exprimant des séquences d'immunoglobuline sensibles au ph
JP2016501230A (ja) * 2012-11-29 2016-01-18 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅＬＬＣ 活性化プロテインＣ（ａＰＣ）に対するモノクローナル抗体
BR112015012458A2 (pt) * 2012-11-29 2018-02-06 Bayer Healthcare Llc anticorpos monoclonais humanizados contra a proteína c ativada e usos destes
JP6445440B2 (ja) * 2013-09-20 2018-12-26 中外製薬株式会社 抗プロテインｃ抗体による出血性疾患の治療
GB201322091D0 (en) 2013-12-13 2014-01-29 Cambridge Entpr Ltd Modified serpins for the treatment of bleeding disorders
WO2015179435A1 (fr) 2014-05-19 2015-11-26 Bayer Healthcare Llc Anticorps monoclonaux humanisés optimisés dirigés contre la protéine c activée et leurs utilisations
US11077187B2 (en) 2015-11-17 2021-08-03 Oklahoma Medical Research Foundation Epitope of optimized humanized monoclonal antibodies against activated protein C and uses thereof
BR112019012354A2 (pt) 2016-12-21 2019-11-26 Teneobio Inc anticorpos apenas de cadeia pesada anti-bcma
IL271194B2 (en) 2017-06-20 2024-10-01 Teneobio Inc Anti-bcma heavy chain-only antibodies
TW201906868A (zh) * 2017-07-07 2019-02-16 日商第一三共股份有限公司 抗蛋白ｃ抗體
CA3099487A1 (fr) 2017-07-20 2019-01-24 Nbe-Therapeutics Ag Anticorps humains se liant a ror2
DK3682247T3 (da) * 2017-09-13 2022-03-21 Brahms Gmbh Proadrenomedullin som markør for unormale blodpladeniveauer
WO2020051277A1 (fr) * 2018-09-06 2020-03-12 Board Of Regents, The University Of Texas System Traitement et prévention de l'arthropathie hémophilique avec un anticorps contre le récepteur cellulaire endothélial de la protéine c (epcr)
CA3116539C (fr) * 2018-10-18 2023-10-03 Oklahoma Medical Research Foundation Biomarqueurs d'indice immunitaire d'activite de maladie du lupus erythemateux dissemine (sle) qui caracterise une activite de maladie
CN109897108B (zh) * 2019-03-11 2021-04-02 上海恒赛生物科技有限公司 抗人内皮蛋白c受体的羊驼单域抗体及应用
CN115611986B (zh) * 2021-07-13 2025-08-12 上海莱士血液制品股份有限公司 针对人活化蛋白c的单克隆抗体及其制备和应用
CN118370814A (zh) * 2023-01-20 2024-07-23 上海莱士血液制品股份有限公司 一种抗aPC单克隆抗体的制剂及其应用
KR20250000042A (ko) 2023-06-23 2025-01-02 충남대학교산학협력단 절단 반응성 펩타이드를 발현하는 키메라 t 세포 및 이를 포함하는 감염 질환 치료용 조성물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (fr) * 1991-06-24 1993-01-07 The Scripps Research Institute Polypeptides de la proteine c-activee et anticorps antipeptides, methode de diagnostic et systemes permettant d'inhiber la proteine c-activee, et methodes therapeutiques
WO2002029015A1 (fr) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Dosage destine a la detection rapide de proteine c activees humaine et d'anticorps monoclonal specifiquement dirige contre cette proteine

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7247453B1 (en) * 1988-12-30 2007-07-24 Oklahoma Medical Research Foundation Calcium binding recombinant antibody against protein C
US5202253A (en) * 1988-12-30 1993-04-13 Oklahoma Medical Research Foundation Monoclonal antibody specific for protein C and antibody purification method
US5695993A (en) 1994-08-12 1997-12-09 Oklahoma Medical Research Foundation Cloning and regulation of an endothelial cell protein C/activated protein C receptor
US6953568B1 (en) 1998-08-25 2005-10-11 Oklahoma Medical Research Foundation Targeting of molecules to large vessel endothelium using EPCR
US7423128B2 (en) 2004-11-03 2008-09-09 Amgen Fremont Inc. Anti-properdin antibodies, and methods for making and using same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000102A1 (fr) * 1991-06-24 1993-01-07 The Scripps Research Institute Polypeptides de la proteine c-activee et anticorps antipeptides, methode de diagnostic et systemes permettant d'inhiber la proteine c-activee, et methodes therapeutiques
WO2002029015A1 (fr) * 2000-10-02 2002-04-11 Oklahoma Medical Research Foundation Dosage destine a la detection rapide de proteine c activees humaine et d'anticorps monoclonal specifiquement dirige contre cette proteine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHOGNOT D ET AL: "Identification of protein C epitopes altered during its nanoencapsulation", JOURNAL OF PROTEIN CHEMISTRY, XX, XX, vol. 18, no. 7, 1 October 1999 (1999-10-01), pages 779 - 784, XP002473395, ISSN: 0277-8033 *
MOSNIER LAURENT O ET AL: "Activated protein C variants with normal cytoprotective but reduced anticoagulant activity", BLOOD 15 SEP 2004,, vol. 104, no. 6, 15 September 2004 (2004-09-15), pages 1740 - 1744, XP002506855 *

Also Published As

Publication number Publication date
US8153766B2 (en) 2012-04-10
MX2010004615A (es) 2010-07-06
CN105153308A (zh) 2015-12-16
EP2205638A2 (fr) 2010-07-14
KR20150092358A (ko) 2015-08-12
JP2014237651A (ja) 2014-12-18
RU2012150953A (ru) 2014-06-10
CN101918453A (zh) 2010-12-15
CA2703738A1 (fr) 2009-04-30
CA2703738C (fr) 2018-02-27
US9127072B2 (en) 2015-09-08
IL205284A0 (en) 2010-12-30
US20090110683A1 (en) 2009-04-30
JP6117741B2 (ja) 2017-04-19
KR101856210B1 (ko) 2018-05-09
WO2009055669A2 (fr) 2009-04-30
US20150344588A1 (en) 2015-12-03
BRPI0818865A2 (pt) 2015-05-05
IL220622A0 (en) 2012-08-30
US20120164150A1 (en) 2012-06-28
EP2205638B1 (fr) 2017-03-01
CN103232541A (zh) 2013-08-07
RU2010121148A (ru) 2011-12-10
KR20100116166A (ko) 2010-10-29
JP2011500843A (ja) 2011-01-06
AU2008316661B2 (en) 2013-05-23
AU2008316661A1 (en) 2009-04-30
RU2539729C2 (ru) 2015-01-27
JP2013049694A (ja) 2013-03-14
ZA201105704B (en) 2014-05-28
IL205284A (en) 2014-06-30

Similar Documents

Publication Publication Date Title
WO2009055669A3 (fr) Anticorps monoclonaux contre la protéine c activée
WO2008070344A3 (fr) Compositions et procédés permettant une liaison sphingosine-1-phosphate
WO2008097439A3 (fr) Anticorps contre des maladies auto-immunes pour traiter le pemphigus
WO2009052431A3 (fr) Agents de liaison au cd19 et utilisations de ceux-ci
WO2008100624A3 (fr) Anticorps contre erbb3 et leur utilisation
WO2005103081A3 (fr) Anticorps monoclonaux humains diriges contre cd20
WO2008064292A3 (fr) Neutralisation d'anticorps monoclonaux contre le récepteur nogo-66 (ngr) et leurs utilisations
WO2009083009A3 (fr) Anticorps monoclonaux anti-cd32b
WO2008097461A3 (fr) Hepcidine, antagonistes de l'hepcidine, et procédés d'utilisation
WO2008150946A8 (fr) Anticorps humanisés qui se lient au globulomère aβ(1-42) et leurs utilisations
WO2007058823A3 (fr) Anticorps anti-egfr
WO2009052400A8 (fr) Anticorps qui se lient à la ngal des mammifères et utilisations de ceux-ci
TW200740849A (en) Dual variable domain immunoglobulin and uses thereof
WO2008024188A8 (fr) Immonuglobine à double domaine variable et utilisations de celle-ci
WO2013119966A3 (fr) Anticorps et autres hétéromultimères monocaténaires
WO2010032059A3 (fr) Agents de liaison ciblés dirigés sur cd105 et leurs utilisations
WO2009071696A3 (fr) Molécules d'anticorps humanisés spécifiques pour il-31
WO2008024337A3 (fr) Composés et procédés d'inhibition de l'interaction de protéines bcl avec des partenaires de liaison
WO2006084264A3 (fr) Variants d'anticorps et utilisations
MY159201A (en) Humanized anti-cxcr5 antibodies, derivatives thereof and their uses
WO2009013543A3 (fr) Agents de liaisons ciblés dirigés vers kdr, et utilisations de ceux-ci - 035
WO2010045388A3 (fr) Utilisation des protéines de liaison aux mmp-9 et mmp-12 dans le traitement et la prévention de la sclérose systémique
WO2008151819A3 (fr) Traitement de tumeurs à l'aide d'un anticorps anti-l1 spécifique
WO2011053565A3 (fr) Compositions et méthodes de détection d'une tauopathie
WO2010118203A3 (fr) Molécules de liaison à l'endosialine

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880121024.5

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08841295

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 205284

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2703738

Country of ref document: CA

Ref document number: 2010531275

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2010040674

Country of ref document: EG

Ref document number: MX/A/2010/004615

Country of ref document: MX

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008316661

Country of ref document: AU

REEP Request for entry into the european phase

Ref document number: 2008841295

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2008841295

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2008316661

Country of ref document: AU

Date of ref document: 20081024

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3026/CHENP/2010

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 20107011548

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2010121148

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: 220622

Country of ref document: IL

ENP Entry into the national phase

Ref document number: PI0818865

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20100427